K-ras antisense gene therapy (Keio/Natl Cancer Ctr)

N/A

Report date: 2025/03/20 20:00:06

Base Information

Drug NameK-ras antisense gene therapy (Keio/Natl Cancer Ctr)
Drug Alias NameAxCA-AS-K-ras
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adenoviral vector
Mechanisms of ActionV-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog inhibitors
TargetsGTPase KRas
Therapy Area/IndicationsColorectal Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryJapan
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesKeio University
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNational Cancer Center Of JapanKeio University
Active IndicationsN/A
Inactive IndicationsColorectal Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A